Endocrine Abstracts

Objective: Graves’ orbitopathy (GO) is an autoimmune disease that affects about 25% of the patients with Graves’ disease. The thyrotropin receptor (TSHR) is the main autoantigen of GO. Somatostatin receptors (SSR) are expressed by orbital fibroblasts (OB) of GO patients. Pasireotide (SOM230) is a somatostatin analog that has a great affinity for the type 1 and type 5 SSRs and inhibits both orbital human lymphocyte and OB proliferation in vitro. Therefore it is intere...

Objectives: Evaluate the benefit of postsurgical radioactive iodine (RAI) in patients with differentiated thyroid cancer (DTC) at low to intermediate risk of recurrent disease in whom not routinary use of RAI is recommendedMethods: We retrospectively evaluated 1316 patients with DTC diagnosed between 2009-2015. ATA low (LR) and intermediate (IR) risk were included in the study (PTC: tumor size > 1 cm, microscopic extrathyroidal invasion, <5 micro...

Background: Graves’ ophthalmopathy (GO) is an autoimmune disease that affects particularly the retrobulbar soft tissues and represents the most common extrathyroidal manifestation of Graves’ disease (GD). Some studies suggest that GO in newly diagnosed patients in recent years has a trend towards a less severe clinical presentation, moreover we have no studies that focus the trend of clinical presentation of GO in the last decade on the population of our area.<p ...

Introduction: Oxidative stress (OX) plays a role in the pathogenesis of moderate to severe Graves’ ophthalmopathy (AMS-GO).Aim: We evaluated the impact of clinical conditions related to OX on the outcome of parenteral glucocorticoids (PGLUC) therapy in AMS-GO.Methods: We retrospectively evaluated patients with AMS-GO treated with PGLUC from January 2013 to May 2022. GO clinical evaluation was performed at baseline, at 6 (W6), ...

Introduction: Parenteral corticosteroids (PC) are effective for the treatment of active moderate to severe (AMS) Graves’orbitopathy(GO). A correlation of GO activity with cholesterol has been described. No evidences are available about cholesterol levels and the clinical efficacy of PC in AMS-GO.Aim: Was to detect the predictive role of cholesterol on medium term clinical outcome of PC therapy in AMS-GO.Methods: We studied 87...

Background: Tyrosine kinase inhibitors (TKIs) are modern antineoplastic molecules widely used in the medical treatment of many cancers including iodine refractory differentiated thyroid carcer (DTC) and advanced medullary thyroid cancer (MTC). In patients with thyroid gland, TKIs frequently cause a destructive and/or autoimmune thyroiditis with consequent hypothyroidism. However, authors have reported unexpected TSH increase or hypothyroidism even in patients with total thyroi...